New drugs in hematological disorders / 대한내과학회지
Korean Journal of Medicine
;
: 540-551, 2010.
Artículo
en Coreano
| WPRIM
| ID: wpr-74983
ABSTRACT
Modern medical oncology has introduced various anti-cancer drugs since the World War I and II. Unlike for the solid tumors, hematological malignancies had been documented some limitations for curing it with chemotherapeutic agents only. In 1960, Dr. Nowell and Dr. Hungerford had discovered elongated chromosome (Philadelphia chromosome) which has documented as a product of translocation between 9th and 22nd chromosome in the patients with chronic myeloid leukemia. In 1970s, immunochemistry technique using monoclonal antibody has spread world widely and from 1990s, flow cytometry method has been available. In appreciation of these evolutions in basic science, the treatment strategy ofhematological malignancies has changed from the chemotherapeutic agents to targeted agents. Among the targeted agents, some drugs are newly developed and others are recreated as anti-cancer drugs after long-time of discard because of their toxicities or teratogenic effects. Nowadays, we are in the middle of flood of targeted agents, for example, tyrosinekinase inhibitors, epidermal growth factor receptor blockers, farnesyl transferase inhibitors, histone deacetylase inhibitors, and etc. In 21st century, the optimal treatment of hematological malignancies should follow a tailor- made strategy according to the patient and disease itself. In the present article, some representative agents will be introduced in accordance with target diseases.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Transferasas
/
Inmunoquímica
/
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Neoplasias Hematológicas
/
Primera Guerra Mundial
/
Inhibidores de Histona Desacetilasas
/
Receptores ErbB
/
Citometría de Flujo
/
Oncología Médica
Límite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS